guest ::
| Home > Publications Database > CSF Biomarkers of Neuroinflammation in Prediction of Brain Atrophy > print |
| Home > Publications Database > CSF Biomarkers of Neuroinflammation in Prediction of Brain Atrophy > print |
| 001 | 283117 | ||
| 005 | 20260103103704.0 | ||
| 024 | 7 | _ | |a 10.1002/alz70861_108159 |2 doi |
| 024 | 7 | _ | |a 1552-5260 |2 ISSN |
| 024 | 7 | _ | |a 1552-5279 |2 ISSN |
| 037 | _ | _ | |a DZNE-2026-00013 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Özlü, Serap |0 P:(DE-2719)9003486 |b 0 |e First author |u dzne |
| 111 | 2 | _ | |a Alzheimer’s Association International Conference |g AAIC 25 |c Toronto |d 2025-07-27 - 2025-07-31 |w Canada |
| 245 | _ | _ | |a CSF Biomarkers of Neuroinflammation in Prediction of Brain Atrophy |
| 260 | _ | _ | |c 2025 |
| 336 | 7 | _ | |a Abstract |b abstract |m abstract |0 PUB:(DE-HGF)1 |s 1767355036_32513 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |m journal |
| 336 | 7 | _ | |a Output Types/Conference Abstract |2 DataCite |
| 336 | 7 | _ | |a OTHER |2 ORCID |
| 520 | _ | _ | |a BackgroundInflammation is recognized as a key hallmark of Alzheimer’s disease (AD), alongside amyloid beta (Aβ) accumulation and tau pathology. Recent evidence suggests that neuroinflammatory markers in cerebrospinal fluid (CSF) are associated with progressive neurodegeneration and regional brain atrophy. In this study, we investigated the relationship between CSF inflammatory markers and atrophy in the basal forebrain and hippocampus longitudinally.MethodWe included 296 participants (37 with AD dementia, 69 with mild cognitive impairment (MCI), 98 with subjective cognitive decline (SCD) and 92 healthy control) from the DELCODE study. Data included baseline CSF markers, the Aβ42-phosphotau181 ratio, disease diagnosis, ApoE4 status, and longitudinal structural MRI volumes for specific brain regions, with a mean follow-up of 19.8 months (SD = 16.7). Latent factors were previously derived via Bayesian confirmatory factor analysis from 14 CSF markers and classified into Synaptic, Microglia, Chemokine/Cytokine, and Complement groups. We used linear mixed-effects models to assess interactions between latent factors and time on brain regions-controlling for age, sex, education and ApoE4 status- and, based on our systematic review, examined whether neurogranin, sTREM2, ferritin, and YKL40 predicted longitudinal changes.ResultOur findings revealed significant interaction effects between specific biomarkers and regional brain atrophy. Longitudinal atrophy in the hippocampus was significantly associated with higher levels of the synaptic marker (β = -0.018, p = 0.004), sTREM2 (β = -0.012, p = 0.031), and YKL40 (β = -0.022, p = 0.0002). Similarly, increased levels of ferritin (β = -0.040, p = 0.024) and YKL40 (β = -0.041, p = 0.029) were predictive of longitudinal atrophy in the basal forebrain. In contrast, neurogranin and other latent factors—including microglia, chemokine/cytokine, and complement—did not show significant associations with atrophy in either brain region.ConclusionThese results suggest that certain biomarkers, particularly the synaptic latent factor and the individual markers sTREM2, ferritin, and YKL40, are predictive of longitudinal neurodegeneration in key brain regions vulnerable to Alzheimer's disease. The associations found with hippocampal and basal forebrain atrophy highlight the potential of these markers for tracking disease progression and improving early detection strategies. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: pub.dzne.de |
| 700 | 1 | _ | |a Grazia, Alice |0 P:(DE-2719)9001307 |b 1 |u dzne |
| 700 | 1 | _ | |a Dyrba, Martin |0 P:(DE-2719)2810283 |b 2 |u dzne |
| 700 | 1 | _ | |a Brosseron, Frederic |0 P:(DE-2719)2810593 |b 3 |u dzne |
| 700 | 1 | _ | |a Buerger, Katharina |0 P:(DE-2719)2811351 |b 4 |u dzne |
| 700 | 1 | _ | |a Düzel, Emrah |0 P:(DE-2719)2000005 |b 5 |u dzne |
| 700 | 1 | _ | |a Hellmann-Regen, Julian David Nicolai |0 P:(DE-2719)9003016 |b 6 |u dzne |
| 700 | 1 | _ | |a Jessen, Frank |0 P:(DE-2719)2000032 |b 7 |u dzne |
| 700 | 1 | _ | |a Kleineidam, Luca |0 P:(DE-2719)2812139 |b 8 |u dzne |
| 700 | 1 | _ | |a Laske, Christoph |0 P:(DE-2719)2000055 |b 9 |u dzne |
| 700 | 1 | _ | |a Perneczky, Robert |0 P:(DE-2719)2812234 |b 10 |u dzne |
| 700 | 1 | _ | |a Peters, Oliver |0 P:(DE-2719)2811024 |b 11 |u dzne |
| 700 | 1 | _ | |a Priller, Josef |0 P:(DE-2719)2811122 |b 12 |u dzne |
| 700 | 1 | _ | |a Ramirez, Alfredo |0 P:(DE-2719)2812825 |b 13 |u dzne |
| 700 | 1 | _ | |a Schneider, Anja |0 P:(DE-2719)2812035 |b 14 |u dzne |
| 700 | 1 | _ | |a Spottke, Annika |0 P:(DE-2719)2811324 |b 15 |u dzne |
| 700 | 1 | _ | |a Synofzik, Matthis |0 P:(DE-2719)2811275 |b 16 |u dzne |
| 700 | 1 | _ | |a Wiltfang, Jens |0 P:(DE-2719)2811317 |b 17 |u dzne |
| 700 | 1 | _ | |a Teipel, Stefan |0 P:(DE-2719)2000026 |b 18 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1002/alz70861_108159 |g Vol. 21, no. S7, p. e108159 |0 PERI:(DE-600)2201940-6 |n S7 |p e108159 |t Alzheimer's and dementia |v 21 |y 2025 |x 1552-5260 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/283117/files/DZNE-2026-00013.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/283117/files/DZNE-2026-00013.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:283117 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9003486 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 1 |6 P:(DE-2719)9001307 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2810283 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2810593 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)2811351 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2000005 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 6 |6 P:(DE-2719)9003016 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)2000032 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2812139 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2000055 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2812234 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 11 |6 P:(DE-2719)2811024 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2811122 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2812825 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 14 |6 P:(DE-2719)2812035 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-2719)2811324 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2811275 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 17 |6 P:(DE-2719)2811317 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)2000026 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2025-01-06 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-06 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 920 | 1 | _ | |0 I:(DE-2719)1510100 |k AG Teipel |l Clinical Dementia Research (Rostock /Greifswald) |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1011303 |k AG Heneka |l Neuroinflammation, Biomarker |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1111015 |k Clinical Research (Munich) |l Clinical Research (Munich) |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)5000006 |k AG Düzel |l Clinical Neurophysiology and Memory |x 3 |
| 920 | 1 | _ | |0 I:(DE-2719)1011102 |k AG Jessen |l Clinical Alzheimer’s Disease Research |x 4 |
| 920 | 1 | _ | |0 I:(DE-2719)1011201 |k AG Wagner |l Neuropsychology |x 5 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 6 |
| 920 | 1 | _ | |0 I:(DE-2719)5000022 |k AG Dichgans |l Vascular Cognitive Impairment & Post-Stroke Dementia |x 7 |
| 920 | 1 | _ | |0 I:(DE-2719)5000007 |k AG Priller |l Translational Neuropsychiatry |x 8 |
| 920 | 1 | _ | |0 I:(DE-2719)1011101 |k Patient Studies (Bonn) |l Patient Studies (Bonn) |x 9 |
| 920 | 1 | _ | |0 I:(DE-2719)1011305 |k AG Schneider |l Translational Dementia Research (Bonn) |x 10 |
| 920 | 1 | _ | |0 I:(DE-2719)1011103 |k AG Spottke |l Clinical Research Platform (CRP) |x 11 |
| 920 | 1 | _ | |0 I:(DE-2719)1410006 |k AG Wiltfang |l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases |x 12 |
| 980 | _ | _ | |a abstract |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-2719)1510100 |
| 980 | _ | _ | |a I:(DE-2719)1011303 |
| 980 | _ | _ | |a I:(DE-2719)1111015 |
| 980 | _ | _ | |a I:(DE-2719)5000006 |
| 980 | _ | _ | |a I:(DE-2719)1011102 |
| 980 | _ | _ | |a I:(DE-2719)1011201 |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)5000022 |
| 980 | _ | _ | |a I:(DE-2719)5000007 |
| 980 | _ | _ | |a I:(DE-2719)1011101 |
| 980 | _ | _ | |a I:(DE-2719)1011305 |
| 980 | _ | _ | |a I:(DE-2719)1011103 |
| 980 | _ | _ | |a I:(DE-2719)1410006 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|